Resveratrol Alleviates Dextran Sulfate Sodium-Induced Acute Ulcerative Colitis in Mice by Mediating PI3K/Akt/VEGFA Pathway
An erratum on
Resveratrol Alleviates Dextran Sulfate Sodium-Induced Acute Ulcerative Colitis in Mice by Mediating PI3K/Akt/VEGFA Pathway
by Zhu, F., Zheng, J., Xu, F., Xi, Y., Chen, J., and Xu, X. (2021). Front. Pharmacol. 12:693982. doi: 10.3389/fphar.2021.693982
Due to a production error, the latest version of Figure 3 was not published. The corrected Figure 3 appears below.
FIGURE 3. RSV inhibits the PI3K/Akt pathway activation and reduces the VEGFA gene expression. (A) The expression of VEGFA and PI3K and genes in colon tissues were analyzed by RT-qPCR. (B) The expression of VEGFA, PI3K, p-Akt, and Akt protein in colon tissues was detected by Western blot analysis. (C) Expression of VEGFA and Akt protein in colon tissues was analyzed by IHC. (D) The expression of VEGFA and PI3K in colon tissues after the addition of PI3K/Akt activator was determined with RT-qPCR. (E) Western blot analysis of the expression of VEGFA, PI3K, and p-Akt/Akt ratio was in colon tissues after the addition of PI3K/Akt activator. (F) The expression of VEGFA and p-Akt protein in colon tissue after adding PI3K/Akt activator was determined with IHC. #p < 0.05 vs. VEGFA, PI3K, and Akt expression in MG. ##p < 0.01. n 20. Measurement data were expressed by mean ± SD. One-way ANOVA was conducted for multiple group comparison, followed by Tukey’s post hoc test. NG, normal control group; MG, model control group; RG, resveratrol group; PG, positive control group; VEGFA, vascular endothelial growth factor A; 740Y-P, PI3K/Akt activator.
The publisher apologizes for this mistake. The original version of this article has been updated.
Keywords: resveratrol, ulcerative colitis, phosphoinositide 3-kinase, protein kinase B, vascular endothelial growth factor A
Citation: Frontiers Production Office (2021) Erratum: Resveratrol Alleviates Dextran Sulfate Sodium-Induced Acute Ulcerative Colitis in Mice by Mediating PI3K/Akt/ VEGFA Pathway. Front. Pharmacol. 12:797101. doi: 10.3389/fphar.2021.797101
Received: 18 October 2021; Accepted: 18 October 2021;
Published: 02 November 2021.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2021 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org